Why Did Vivos Therapeutics (VVOS) Stock Jump Over 21% After Hours

Benzinga_recent_news04-03

SP Manager LLC and its managing director, Michael C. Skaff, now control 19.9% of VVOS's outstanding common stock, or roughly 2.69 million shares. Their stake is held through three affiliated ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624632490?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/03/Businessman-Watching-Red-Graph-On-Smartp.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-04-03 12:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624632490","market":"sh","top_or_hot":-1,"title":"Why Did Vivos Therapeutics (VVOS) Stock Jump Over 21% After Hours","media":"Benzinga_recent_news","content":"<div>\n<p>SP Manager LLC and its managing director, Michael C. Skaff, now control 19.9% of VVOS's outstanding common stock, or roughly 2.69 million shares. Their stake is held through three affiliated ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/26/04/51643452/why-did-vivos-therapeutics-vvos-stock-jump-over-21-after-hours\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Vivos Therapeutics (VVOS) Stock Jump Over 21% After Hours</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Vivos Therapeutics (VVOS) Stock Jump Over 21% After Hours\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-03 12:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/equities/26/04/51643452/why-did-vivos-therapeutics-vvos-stock-jump-over-21-after-hours><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SP Manager LLC and its managing director, Michael C. Skaff, now control 19.9% of VVOS's outstanding common stock, or roughly 2.69 million shares. Their stake is held through three affiliated ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/26/04/51643452/why-did-vivos-therapeutics-vvos-stock-jump-over-21-after-hours\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.benzinga.com/markets/equities/26/04/51643452/why-did-vivos-therapeutics-vvos-stock-jump-over-21-after-hours","article_id":"2624632490","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/03/Businessman-Watching-Red-Graph-On-Smartp.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/04/51643452/why-did-vivos-therapeutics-vvos-stock-jump-over-21-after-hours","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624632490","pubTimestamp":1775191080,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Vivos Therapeutics shares surge 21.21% after hours as a Michigan-based investor group acquires a 19.9% stake through a $2.39 million private placement.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","BK4150":"赌场与赌博","RSI":"Rush Street Interactive, Inc.","VVOS":"Vivos Therapeutics"},"translate_title":"为什么Vivos Therapeutics(VVOS)股价盘后上涨超过21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VVOS":1.5,"RSI":1},"content_text":"SP Manager LLC and its managing director, Michael C. Skaff, now control 19.9% of VVOS's outstanding common stock, or roughly 2.69 million shares. Their stake is held through three affiliated investment vehicle: V-CO Investors LLC with 3.8%, V-CO Investors 2 LLC with 6.1%, and V-CO Investors 3 LLC with 10%.\nSP Manager LLC often serves as a manager or advisor for specific investment vehicles and private ventures.\nOn March 31, V-CO Investors 3 LLC entered a Securities Purchase Agreement with Vivos, acquiring 1.35 million shares at $1.34 per share for about $1.81 million. This total includes the conversion of a $1.4 million convertible promissory note issued Jan. 15, converted at $1.09 per share plus $0.25 per share to comply with Nasdaq minimum price rules.\nUnder the Securities Purchase Agreement, V-CO Investors 3 LLC received Series A and Series B warrants, each covering 1.78 million shares at an exercise price of $1.09 per share. The agreement also includes a pre-funded warrant for 429,957 shares at $0.0001, with the proceeds intended for general working capital.\nVivos Therapeutics, a Colorado-based medical technology company, has a market capitalization of $12.46 million and a 52-week trading range of $1.09 to $7.95.\nThe stock has a Relative Strength Index (RSI) of 50.49.\nVVOS has fallen 48.64% over the past 12 months, highlighting challenges for its longer-term outlook.\nThe small-cap stock is currently trading near its 52-week low.\nPrice Action: VVOS closed Thursday’s regular session up 3.13% at $1.32, according to Benzinga Pro data.\nBenzinga’s Edge Stock Rankings indicate that VVOS has a negative price trend across all time frames.\nPhoto Courtesy: SuPatMaN on Shutterstock.com\nDisclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624632490","isCrawlerRequest":true}